Why in News:
- The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO)
About the drug
- The drug comes in powder form in sachet, which is taken orally by dissolving it in water.
- It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.
- Selective accumulation is a process where drugs are uniformly distributed in a specific body tissue of interest.
- Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
- Institute of Nuclear Medicine & Allied Sciences (INMAS) is a laboratory of the Defence Research and Development Organisation (DRDO). It focuses on clinical research in nuclear medicine & responding to nuclear accidents and explosions and non-invasive imaging methods with a focus on biological radio-protectors and thyroid disorders.
- DRDO works under the administrative control of the Ministry of Defence. It is working to establish a world class science and technology base for India and provides our Defence Services decisive edge by equipping them with internationally competitive systems and solutions.
- Drugs Controller General of India (DCGI) is the head of department of the Central Drugs Standard Control Organization of the Government of India responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids, vaccines, and sera in India.
- Drugs Controller General of India, comes under the Ministry of Health & Family Welfare.
- DCGI also sets standards for manufacturing, sales, import, and distribution of drugs in India.